Brief: Repare Therapeutics Announces Publication Of Preclinical Data in Nature Demonstrating Potential of RP-6306 In Tumors With CCNE1 Amplification
20/04/2022 16:06
April 20 (Reuters) - Repare Therapeutics Inc RPTX.O :
* REPARE THERAPEUTICS ANNOUNCES PUBLICATION OF PRECLINICAL
DATA IN
NATURE DEMONSTRATING THE POTENTIAL OF PKMYT1 INHIBITOR RP-6306
IN TUMORS WITH CCNE1 AMPLIFICATION
* REPARE THERAPEUTICS - DATA SHOW PKMYT1 INHIBITION IS A
PROMISING
THERAPEUTIC TARGET IN CCNE1-AMPLIFIED CANCERS
* REPARE THERAPEUTICS - RP-6306 IS CURRENTLY BEING EVALUATED
IN
PHASE 1 CLINICAL TRIALS
Source text for Eikon: urn:newsml:reuters.com:*:nBw6TVtjca
Further company coverage: RPTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Repare Therapeutics
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Brief: Repare Therapeutics Announces Acquisition Of Polθ ATPase Inhibitor, RP-3467, By Gilead Sciences For Up To $30 Million In Total Consideration
Brief: Repare Signs Support Agreements With Key Shareholders For Xenotherapeutics Deal
Repare Therapeutics Q2 net loss narrows to $16.7 mln